TITLE

Reply

AUTHOR(S)
Hanabusa, Hideji
PUB. DATE
August 2003
SOURCE
Clinical Infectious Diseases;8/1/2003, Vol. 37 Issue 3, p464
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Responds to comments about the author's article on the sustained viral response (SVR) of HIV-positive and -negative patients with hepatitis C virus (HCV) genotype 1 infections. Link between the degree of virus load reduction during the first phase of treatment and the second-phase decline slope; Evaluation of the dose, frequency and duration of interferon therapy.
ACCESSION #
10590288

 

Related Articles

  • Should Treatment of Hepatitis C in HIV-Seropositive and HIV-Seronegative Patients with Hemophilia Include Induction Doses of Interferon? McGovern, Barbara; Bica, Ioana // Clinical Infectious Diseases;8/1/2003, Vol. 37 Issue 3, p463 

    Presents a letter to the editor of the journal 'Clinical Infectious Diseases' about the inclusion of interferon in the treatment of hepatitis C in HIV-seropositive and -seronegative patients with hemophilia. First phase of viral decline in response to interferon therapy; Treatment of...

  • One full year of treatment is now believed to be best for hepatitis C.  // Modern Medicine;Jul95, Vol. 63 Issue 7, p8 

    Discusses the effectiveness of extending interferon alpha-2b treatment for hepatitis C patients to one year according to an international consensus conference on hepatitis held on May 11-12, 1995 in Los Angeles, California. Standard treatment duration; Sexual transmission; Histologic evidence.

  • Two-pronged attack on hepatitis C.  // Consumer Reports on Health;Apr99, Vol. 11 Issue 4, p6 

    Reports on findings on the effectiveness of using interferon injections with the oral antiviral drug ribavirin to treat hepatitis C, as published in `The New England Journal of Medicine.'

  • Antifibrogenic activity of interferon alpha in chronic hepatitis C. Suou, Takeaki // Journal of Gastroenterology;1999, Vol. 34 Issue 3, p426 

    Editorial. Discusses the antifibrogenic activity of interferon alpha in chronic hepatitis C. Decrease in serum propeptide of type III procollagen levels; Reduction of keloid scarring; Improvement of liver fibrosis in sustained responders to interferon alpha.

  • Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm. Foster, G.R.; Goldin, R.D. // BMJ: British Medical Journal (International Edition);08/23/97, Vol. 315 Issue 7106, p453 

    Assesses the attendance, outcome and compliance with treatment and response to interferon alpha in patients with chronic hepatitis C treated according to a biopsy-based algorithm. Low percentage of patients willing to undergo diagnosis and treatment; Low response rate to interferon; High...

  • Incidence of Side Effects During Therapy with Different Types of Alpha Interferon: A Randomised Controlled Trial Comparing Recombinant Alpha 2b Versus Leukocyte Interferon in the Therapy of Naive Patients with Chronic Hepatitis C. Ascione, Antonio; De Luca, Massimo; Di Costanzo, Giovan Giuseppe; Picciotto, Francesco Paolo; Lanza, Alfonso Galeota; Canestrini, Carmine; Morisco, Filomena; Tuccillo, Concetta; Caporaso, Nicola // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p977 

    Background: Alpha interferon (IFN) alone or in combination with Ribavirin (RBV) is the treatment of choice for HCV related chronic liver disease. There are many types of alpha IFN and to date only few reports are available comparing different types of alpha interferon. We run a randomised...

  • Interferon and Hepatitis C. Terrault, Norah; Wright, Teresa // New England Journal of Medicine;6/1/95, Vol. 332 Issue 22, p1509 

    Editorial. Comments on articles by Tong, et al, and Poynard, et al, in the June 1, 1995 issue of the `New England Journal of Medicine,' which deal with treatment regimens for chronic hepatitis C. Findings about transfusion-associated chronic hepatitis C; Study of interferon treatment regimens.

  • Hepatitis C: One year of interferon is much better than 6 months.  // Modern Medicine;Jul97, Vol. 65 Issue 7, p32 

    Reports on an Italian study showing the effectiveness of a one-year interferon therapy in patients with suspected hepatitis C virus. Results from a sample of patients with chronic hepatitis who had first been treated with recombinant alfa-2b interferon administered at different dosages; Reduced...

  • Hepatitis C Rx in a high-risk patient. M.O.R. // Cortlandt Forum;01/25/98, Vol. 11 Issue 1, p82 

    Responds to an inquiry on whether a patient exposed to hepatitis C needs to be treated with interferon alpha. Results of diagnostic procedures; Medical history.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics